NASDAQ · Financial Statements
Quince Therapeutics, Inc. (QNCX) Financial Statements
$31.73
NASDAQ: QNCX
Market Cap $8.83M
Overview Financials Dividend Quince Therapeutics, Inc. most recently reported annual revenue of $0, net profit of $-84.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-90.0M $-52.0M $-35.0M $-57.0M $-50.0M Net Profit $-90.0M $-52.0M $-31.0M $-57.0M $-84.0M EPS $-606.00 $-308.00 $-168.00 $-262.00 $-336.00 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $133.0M $104.0M $180.0M $114.0M $94.0M Total Liabilities $15.0M $3.0M $95.0M $84.0M $129.0M Cash $70.0M $45.0M $21.0M $6.0M $6.0M Borrowings $1.0M $0 $14.0M $15.0M $18.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-63.0M $-44.0M $-18.0M $-32.0M $-41.0M Investing Cash Flow $59.0M $18.0M $-6.0M $22.0M $23.0M Financing Cash Flow $0 $0 $0 $-5.0M $0 Net Cash Flow $3.0M $-25.0M $-24.0M $-15.0M $0 Free Cash Flow $-63.0M $-44.0M $-18.0M $-32.0M $-42.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.02 EV / EBITDA 1.48 FCF Yield -532.05% Quick Ratio 14.52 Interest Coverage 0.00 Return 1Y -94.63% Return 3Y -94.30% Return 5Y -99.83%
Screens featuring this stock